GE
GE9.F Genmab A/S
- Market cap
- EUR 14.0B
- P/E
- 99.3x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is GE9.F undervalued?
Graham numberThe Graham number of Genmab A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genmab A/S fundamental analysis
No fundamental analysis for Genmab A/S yet.
Genmab A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…
Full company profileGenmab A/S financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genmab A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 664M | 850M | 1.13B | 1.82B | 2.37B | 3.03B | 5.37B | - | - | - | - |
| Gross Profit | 664M | 850M | 1.13B | 1.82B | 2.37B | 3.03B | 5.37B | - | - | - | - |
| Operating Income | 69.3M | 265M | 554M | 1.05B | 1.37B | 1.38B | 2.64B | - | - | - | - |
| Net Income | 112M | 301M | 764M | 1.19B | 1.10B | 1.47B | 2.17B | - | - | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 1.73B | 2.87B | 3.90B | 5.24B | 6.60B | 8.46B | 15.1B | - | - | - | - |
| Total Liabilities | 1.07B | 834M | 416M | 412M | 331M | 447M | 1.10B | - | - | - | - |
| Shareholders' Equity | 660M | 2.03B | 3.49B | 4.83B | 6.27B | 8.01B | 14.0B | - | - | - | - |
| Cash & Short-term Investments | 168M | 359M | 874M | 307M | 1.35B | 533M | 3.55B | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -128M | 133M | 311M | 328M | 1.59B | 1.02B | 1.33B | 6.43B | 2.23B | 3.91B | - |
| Capital Expenditure | 7.64M | 12.2M | 9.44M | 12.3M | 88.5M | 72.0M | 79.0M | 307M | 252M | 317M | 0.00 |
| Ratios | |||||||||||
| ROE | 17.0% | 14.8% | 21.9% | 24.6% | 17.6% | 18.4% | 15.4% | - | - | - | - |
| ROA | 6.5% | 10.5% | 19.6% | 22.7% | 16.7% | 17.4% | 14.3% | - | - | - | - |
| Net Profit Margin | 16.9% | 35.4% | 67.4% | 65.4% | 46.7% | 48.7% | 40.4% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genmab A/S dividends
Genmab A/S has not paid dividends in the last 9 fiscal years.
Who owns Genmab A/S
- Insiders 1.12%
- Institutions 46.58%
- Public & others 52.30%
- Shares outstanding 61.5M
- Free float 58.9M
Genmab A/S company profile
- Company name
- Genmab A/S
- Ticker
- GE9.F
- ISIN
- DK0010272202
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 3,244
- Fiscal year end
- December
- Address
- Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
- Phone
- 45 70 20 27 28
- Website
- genmab.com
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Genmab A/S management
10- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · born 1961
- Mr. Anthony Pagano CPAExecutive VP & CFO · born 1978
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · born 1968
- Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · born 1971
- Mr. Christopher CozicExecutive VP & Chief People Officer · born 1978
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · born 1971
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · born 1975
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · born 1958
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · born 1973
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · born 1973